Literature DB >> 9437458

Economic research on Alzheimer disease: a review of the literature.

R L Ernst1, J W Hay.   

Abstract

The present review discusses the economic research to date on Alzheimer disease (AD). It focuses on estimates of the costs of AD and on economic evaluations of interventions in the disease. Empirical and conceptual issues concerning the interpretation of costs and the uses of evaluative methodologies also are discussed. We conclude that estimates of the national costs of AD are open to a large margin of uncertainty. We conclude further that significant opportunities exist for new cost-effectiveness or cost-benefit analyses of AD treatments, patient care options, and counselling, respite, or similar programs for AD caregivers.

Entities:  

Mesh:

Year:  1997        PMID: 9437458

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  24 in total

Review 1.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?

Authors:  Sandra Nocera; Dario Bonato; Harry Telser
Journal:  Int J Health Care Finance Econ       Date:  2002-09

4.  Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors.

Authors:  F Huang; M Buttini; T Wyss-Coray; L McConlogue; T Kodama; R E Pitas; L Mucke
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  Longitudinal Associations Between Visual Impairment and Cognitive Functioning: The Salisbury Eye Evaluation Study.

Authors:  D Diane Zheng; Bonnielin K Swenor; Sharon L Christ; Sheila K West; Byron L Lam; David J Lee
Journal:  JAMA Ophthalmol       Date:  2018-09-01       Impact factor: 7.389

6.  The measurement of everyday cognition (ECog): scale development and psychometric properties.

Authors:  Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Deborah Cahn-Weiner; William Jagust; Kathleen Baynes; Charles Decarli
Journal:  Neuropsychology       Date:  2008-07       Impact factor: 3.295

Review 7.  Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  H M Lamb; K L Goa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.

Authors:  Dong-Churl Suh; Simu K Thomas; Elmira Valiyeva; Stephen Arcona; Lien Vo
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

9.  Assessment of dentally related functional competency for older adults with cognitive impairment--a survey for special-care dental professionals.

Authors:  Xi Chen; Jennifer J J Clark
Journal:  Spec Care Dentist       Date:  2012-12-26

10.  Prevalence of cognitive impairment without dementia in the United States.

Authors:  Brenda L Plassman; Kenneth M Langa; Gwenith G Fisher; Steven G Heeringa; David R Weir; Mary Beth Ofstedal; James R Burke; Michael D Hurd; Guy G Potter; Willard L Rodgers; David C Steffens; John J McArdle; Robert J Willis; Robert B Wallace
Journal:  Ann Intern Med       Date:  2008-03-18       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.